TECHNOLOGY LICENSING OPPORTUNITY: Peptoid-Based Chelating Ligands for Selective Metal Chelation

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

TRIAD - DOE CONTRACTOR

Contract Value

Not provided

Codes & Classification
Solicitation Number

S-133639

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

6632

Additional Details
Set Aside

NONE

Place of Performance

Los Alamos, New Mexico, UNITED STATES

SourceSAM
The Department of Energy, through its Los Alamos National Laboratory (LANL) and managed by TRIAD as the DOE contractor, is announcing a technology licensing opportunity for its patented innovation: Peptoid-Based Chelating Ligands for Selective Metal Chelation. This special notice is not a solicitation for external development services, but rather an invitation for companies to license and commercialize this advanced technology. The core purpose of this opportunity is to facilitate the transfer of LANL’s proprietary peptoid-based chelating ligand technology into the commercial sector, enabling new solutions for selective metal ion capture and retention. The technology is designed to address limitations of existing chelators, particularly in challenging environments where traditional agents degrade or lack specificity. By leveraging cyclic peptoid scaffolds—molecules with side chains tailored for metal binding—licensees can access a highly tunable platform capable of targeting hard metal ions such as actinides and lanthanides with exceptional selectivity and stability. Key technical features include the use of peptoid chains cyclized into ring structures, with side-chain chemistry and binding group spacing adjustable to optimize affinity for specific metals. The ligands’ resistance to hydrolysis under physiological and harsh process conditions sets them apart from conventional peptide-based chelators, ensuring sustained activity in demanding applications. Functional groups such as catecholates, phosphonates, amines, guanidinium, phosphoramidates, N-hydroxypyridones, and CMPO-like moieties can be incorporated to further refine binding profiles. The modular design allows for customization of linker length, hydrophobicity, hydrophilicity, and the number of coordinating groups, supporting both strong retention and controlled release of target ions. Expected deliverables under this licensing opportunity include the right to utilize LANL’s patented technology (US Patent Nos. 11,254,708 and 11,859,018; LA-UR-26-23913) for commercial development and deployment. Licensees may pursue exclusive or non-exclusive agreements, depending on their business needs and the intended market applications. Potential applications span a broad range of sectors, including: - Environmental remediation and waste handling (e.g., actinide capture, metal cleanup) - Medical chelation therapy (support for metal poisoning treatment) - Medical imaging (contrast agent development) - Drug delivery (as carriers or targeting agents) - Separations and purification (selective recovery of valuable metals) - Radiotherapy support (targeted metal-based delivery systems) The technology is currently at Technology Readiness Level (TRL) 4, indicating that it has been validated in a laboratory environment and is ready for further development and commercialization. The contracting entity for this opportunity is TRIAD, operating as a federal office under the Department of Energy at Los Alamos National Laboratory, located in Los Alamos, New Mexico (NAICS Code 541714: Research and Development in Biotechnology, except Nanobiotechnology; Product Service Code 6632). There are no set-aside requirements associated with this notice. Interested parties are encouraged to contact the LANL Technology Partnerships Office for further information and to initiate discussions regarding licensing agreements. The primary and secondary contacts for this opportunity are Caleb Ledgerwood and Lindsay Augustyn, both reachable at [email protected]. Additional details about LANL’s licensing program and available technologies can be found at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology and m.lanl.gov/tech-search. This notice remains active, with a response deadline of June 30, 2026. Contractors and companies with expertise in biotechnology, chelation chemistry, or related fields are encouraged to evaluate this opportunity for alignment with their strategic objectives and capabilities.